Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 359

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 359
---
 | Reviewing the appropriateness of the disclosures                
 made by the Directors in the Consolidated Financial Statements. |

We have served as the Group’s auditor since
2020.

Mazars LLP

London, England

April 18, 2024

| F-22 |

Consolidated
StatementS of Comprehensive Income

For the year ended
31 December

|                                                                        |     | Note |     | 2023 £’000 |    |     | 2022 £’000 |   |     | 2021 £’000 |   |
| Revenue                                                                |     |    3 |     |        381 |    |     |        699 |   |     |        578 |   |
| Other income                                                           |     |      |     |         14 |    |     |         22 |   |     |         24 |   |
| Research and development costs                                         |     |      |     |     (4,067 | )  |     |     (5,111 | ) |     |     (4,654 | ) |
| Administrative costs                                                   |     |      |     |     (4,342 | )  |     |     (4,542 | ) |     |     (2,946 | ) |
| Loss from operations                                                   |     |    4 |     |     (8,014 | )  |     |     (8,932 | ) |     |     (6,998 | ) |
| Finance income                                                         |     |    6 |     |        570 |    |     |        497 |   |     |        936 |   |
| Finance expense                                                        |     |    6 |     |        (41 | )  |     |        (53 | ) |     |        (44 | ) |
| Loss before tax                                                        |     |      |     |     (7,485 | )  |     |     (8,488 | ) |     |     (6,106 | ) |
| Taxation                                                               |     |    7 |     |        406 |    |     |        832 |   |     |        646 |   |
| Loss for the year attributable to the owners of the parent             |     |      |     |     (7,079 | )  |     |     (7,656 | ) |     |     (5,460 | ) |
| Other comprehensive income:                                            |